Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIM2b
- Development stage
- Phase 1
- Lead developer
- Beta Innov
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
BIM2b is a first-in-class therapeutic peptide developed by Beta Innov for the treatment of glioblastoma multiforme (GBM). It is a 12-amino acid peptide designed to target the CD44 receptor, a cell-surface glycoprotein that is highly overexpressed in high-grade gliomas and other solid tumors. CD44 serves as the primary receptor for hyaluronic acid (HA) and plays a critical role in tumor cell adhesion, migration, proliferation, and resistance to standard therapies. BIM2b acts by disrupting the interaction between CD44 and its ligands or co-receptors, thereby inhibiting downstream oncogenic signaling pathways that drive tumor invasiveness. The drug is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with recurrent glioblastoma.
02
Targets
Beyond the preview
Go deeper on BIM2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIM2b.